miR-6805-5p as a biomarker of cisplatin-induced nephrotoxicity in patients with head and neck cancer

• Egile Nagusiak: Nadine De Godoy Torso (Egilea), Julia Coelho França Quintanilha (Egilea), Maria Aparecida Cursino (Egilea), Eder De Carvalho Pincinato (Egilea), Pía Loren (Egilea), Luis A. Salazar (Egilea), Carmen Silvia Passos Lima (Egilea), Patricia Moriel (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2023-11-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction: The standard treatment for head and neck squamous cell carcinoma (HNSCC) is cisplatin chemoradiotherapy. One of the main treatment adverse reactions is nephrotoxicity, for which there is currently no adequate specific and sensitive biomarker. Thus, this study aimed to evaluate the use...